Brazil vs Ethiopia: Average cost of multi drug-resistant tuberculosis treatment
Brazil
4,102 constant 2022 US$
in 2024
Ethiopia
5,583 constant 2022 US$
in 2024
Brazil rank
10th
Ethiopia rank
7th
Average cost of multi drug-resistant tuberculosis treatment over time
- Brazil
- Ethiopia
How they compare
Ethiopia currently reports 5,583 constant 2022 US$ against 4,102 constant 2022 US$ in Brazil, a difference of 1,481 constant 2022 US$.
That makes Ethiopia's figure about 1.4 times Brazil's.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Ethiopia ahead.
Brazil ranks 10th and Ethiopia ranks 7th of 92 countries.
Ethiopia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Brazil | Ethiopia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,083 constant 2022 US$ | 3,815 constant 2022 US$ | 732 constant 2022 US$ | Ethiopia |
| 2020s | 4,011 constant 2022 US$ | 5,661 constant 2022 US$ | 1,650 constant 2022 US$ | Ethiopia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Brazil or Ethiopia?
- Ethiopia, at 5,583 constant 2022 US$ against 4,102 constant 2022 US$ in Brazil as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Brazil and Ethiopia?
- 1,481 constant 2022 US$, with Ethiopia ahead.
- How many years of comparable data are there for Brazil and Ethiopia?
- 7 years are reported by both, from 2017 to 2024.
- How do Brazil and Ethiopia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Brazil ranks 10th and Ethiopia ranks 7th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.